2nd How to Diagnose and Treat ACUTE LEUKAEMIA
March 13-15, 2020 - Budapest, Hungary
Chairs: Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock

Friday, March 13th, 2020

08:45-09:00  Welcome

SESSION I – Rare subsets of acute leukaemia
Chair: Gail Roboz (New York)

09:00-09:20  Case-based lecture: Mixed phenotype acute leukaemias (B/M)  Charles Mullighan (Memphis)
09:20-09:25  Discussion

09:25-09:45  Case-based lecture: Interface acute leukaemias (T/M)  Jonathan Bond (Dublin)
09:45-09:50  Discussion

09:50-10:10  Case-based lecture: Germline predisposition to AML  Lucy Godley (Chicago)
10:10-10:15  Discussion

Brief oral communication
10:15-10:20  Dasatinib Inhibits FLT3/itd and PTPN11 Mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases  Nathali Kaushansky (Rehovot)
10:20-10:23  Discussion

10:23-10:45  Panel discussion

10:45-11:15  Coffee Break

SESSION II – Tracking leukaemic stem cells (LSCs)
Chair: Sylvie Freeman (Birmingham)

11:15-11:35  Case-based lecture: LSC signature  Andre Schuh (Toronto)
11:35-11:40  Discussion

11:40-12:00  Case-based lecture: Flow identification and monitoring of leukaemia stem cells  Jacqueline Cloos (Amsterdam)
12:00-12:05  Discussion
21/02/20

12:05-12:25  Case-based lecture:  Emmanuelle Clapier (Paris)
MRD monitoring in Ph-positive ALL
12:25-12:30  Discussion

Brief oral communication
12:30-12:35  Circulating microRNAs Behaving as Minimal Residual Disease Biomarkers in Childhood ALL  Dániel János Erdélyi (Budapest)
12:35-12:38  Discussion

12:38-13:00  Panel discussion

13:00-14:40  Lunch

13:30-14:30  SATELLITE SYMPOSIUM:
T-cell engaging immuno-oncology therapy in ALL: from clinical trials to real-world evidence
Speakers: Nicolas Boissel (Paris), Christina Peters (Vienna)

This symposium is organised and funded by Amgen

SESSION III – Routine diagnosis gene expression and mutational profiling
Chair: Oliver Ottmann (Cardiff)

14:40-15:00  Case-based Lecture:  Sabina Chiaretti (Rome)
Ph-like ALL diagnosis
15:00-15:05  Discussion

15:05-15:25  Case-based lecture:  Josep-Maria Ribera (Barcelona)
Minimal / optimal gene panel in ALL?
15:25-15:30  Discussion

15:30-15:50  Case-based lecture:  Lars Bullinger (Berlin)
Minimal / optimal gene panel in AML?
15:50-15:55  Discussion

Brief oral communication
15:55-16:00  Integrated Whole Genome-Transcriptome Sequencing  Georgina Ryland (Melbourne)
Compared to Conventional Diagnostic Testing in Adult B-ALL
16:00-16:03  Discussion

15:55-16:25  Panel discussion

16:25-16:55  Coffee break

16:55-17:35  DEBATE 1 – All patients with intermediate-risk AML must be transplanted
Chair: Andrew Wei (Melbourne)

Audience votes “yes” or “no”

16:55-17:10  Yes  Charles Craddock (Birmingham)
17:10-17:15  Discussion

17:15-17:30  No  Gail Roboz (New York)
17:30-17:35  Discussion

Audience votes again

17:35-18:05  INTERACTIVE CASES 1 – Mutation-based therapy off-label
Chair: Jorge Sierra (Barcelona)

17:35-17:42  Targeted therapy for Ph-like ALL
Discussion
Sarah Tasian (Philadelphia)

17:42-17:45  Discussion

17:45-17:52  Mutation-based therapy off-label - GO for AML salvage therapy
Discussion
Nicolas Boissel (Paris)

17:52-17:55  Discussion

17:55-18:02  FLT3 inhibitors post-transplantation
Discussion
Andreas Burchert (Marburg)

18:02-18:05  Discussion

18:05-19:05  ROUNDTABLE 1 – Should we really use new targeted inhibitors as single agents ?
Chair: Christoph Röllig (Dresden)

18:05-18:25  Next-generation FLT3 inhibitors
Discussion
Alexander Perl (Philadelphia)

18:25-18:45  The role of IDH1/2 Inhibitors as monotherapy
Discussion
Courtney DiNardo (Houston)

18:45-18:55  Discussion

18:55  Mentored Poster Walks and Welcome Get Together Stand up Buffet Dinner

Saturday, March 14th, 2020

08:00-9:00  3 Simultaneous Meet the Expert sessions

1. CNS prophylaxis and treatment in ALL
   Wendy Stock (Chicago)

2. MRD as a treatment-stratifying tool in AML
   Sylvie Freeman (Birmingham)

3. Acute leukaemia and pregnancy
   Nicolas Boissel (Paris)

SESSION IV – Addition of a 3rd agent to frontline 7+3
Chair: Andrew Wei (Melbourne)

09:10-09:30  Case-based lecture:
Midostaurin
Peter Paschka (Ulm)

09:30-09:35  Discussion

09:35-09:55  Case-based lecture:
Addition of gemtuzumab ozogamicin to front line 3+7 chemotherapy
Juliette Lambert (Versailles)

09:55-10:00  Discussion

10:00-10:20  Case-based lecture:
Nucleoside analogs
Thomas Pabst (Bern)

10:20-10:25  Discussion
**Brief oral communication**

10:25-10:30  *Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML*  
Keith W. Pratz (Baltimore)*

10:30-10:33  Discussion

10:25-10:55  Panel discussion

10:55-11:25  **Coffee Break and Poster viewing**

11:25-12:20  **ROUNDTABLE 2 – Curative options for older AML**  
Chair: Alexander Perl (Philadelphia)

11:25-11:40  Current intensive therapy of older AML patients in 2020  
Claude Gardin (Bobigny)

11:40-11:55  Liposomal daunorubicin/cytarabine  
Jorge E. Cortes (Augusta)

11:55-12:10  Defining the role of Venetoclax in older patients with AML  
Andrew Wei (Melbourne)

12:10-12:20  Discussion

12:20-12:40  **INTERACTIVE CASES 2**  
Chair: Arnold Ganser (Hannover)

12:20-12:27  Management of high WBC APL  
Pau Montesinos (Valencia)

12:27-12:30  Discussion

12:30-12:37  APL relapse after previous arsenic therapy  
Lionel Ades (Paris)

12:37-12:40  Discussion

12:40-14:20  Lunch

**13:10-14:10  SATELLITE SYMPOSIUM:**  
AML treatment: Where are we heading?  
Chair: Andrew Wei (Melbourne)  
Speakers: Konstanze Döhner (Ulm), Gail Roboz (New York)

*This symposium is organized and funded by Celgene. A Bristol-Myers Squibb company*

14:20-15:00  **DEBATE 2 – Best treatment for NPM1-mutated AML in the next future ?**  
Chair: Hervé Dombret (Paris)

Audience votes

14:20-14:35  Treatment of NPM1-mutated AML: Intensive Standard Treatment!  
Christoph Röllig (Dresden)

14:35-14:40  Discussion

14:40-14:55  Targeted agents  
Ali Bazarbachi (Beyrouth)

14:55-15:00  Discussion

Audience votes again
15:00-15:25  **Coffee break and Poster Viewing**

**SESSION V - Allogeneic hematopoietic stem cell transplantation (HSCT)**

Chair: Charles Craddock (Birmingham)

Jean-Hugues Dalle (Paris)

15:45-15:50  **Discussion**

15:50-16:10  Case-based lecture: Haplo-identical HSCT  
Jorge Sierra (Barcelona)

16:10-16:15  **Discussion**

16:15-16:35  Case-based lecture: Prevention and treatment of VOD – 100 years after the “Senecio Disease”  
Tiago Nava (Geneva)

16:35-16:40  **Discussion**

**Brief oral communication**

16:40-16:45  **Detectable Minimal Measurable Disease By Flow Cytometry before Allogeneic Transplantation Is a Factor of Poor Outcomes in Acute Myeloid Leukemia**  
Claudia Núñez-Torrón Stock (Madrid)

16:45-16:48  **Discussion**

16:48-17:05  **Panel discussion**

**17:20-18:20  SATELLITE SYMPOSIUM:**

**AML: Bringing precision medicine and MRD into clinical strategies**

Chair: Jorge Sierra (Barcelona)

Speakers: Lionel Adès (Paris), Lars Bullinger (Berlin), Jorge Sierra (Barcelona)

*This symposium is organised and funded by Novartis*

---

**Sunday, March 15th, 2020**

08:00-09:00  **3 Simultaneous Breakfast Meet the Expert Sessions**

1. Therapy-related leukaemias  
Arnold Ganser (Hannover)

2. How I treat Ph+ ALL  
Oliver Ottmann (Cardiff)

3. How I treat older ALL  
Hervé Dombret (Paris)

**08:30-09:30  SATELLITE SYMPOSIUM:**

**Waking up to a new decade of individualized treatment for AML**

Chair: Jorge Sierra (Barcelona)

Speakers: Jacqueline Cloos (The Netherlands), Pau Montesinos (Valencia), Andrew Wei (Melbourne)

*This symposium is organised and funded by Astellas*
SESSION VI – Immunotherapy for acute leukaemia
Chair: Wendy Stock (Chicago)

09:40-10:00 Case-based lecture: Use of blinatumomab in ALL
Max Topp (Würzburg)
10:00-10:05 Discussion

10:05-10:25 Case-based lecture: CAR T-cells for precursor B-cell ALL
Françoise Méchinaud (Paris)
10:25-10:30 Discussion

10:30-10:50 Case-based lecture: Immune check-point inhibitors in acute leukaemia
Navel Daver (Houston)
10:50-10:55 Discussion

Brief oral communication
10:55-11:00 Phase 1b Multicenter, Open-Label Study of the Anti–TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Andrew Wei (Melbourne)
11:00-11:03 Discussion

11:03-11:25 Panel discussion

11:25-11:55 Coffee break

11:55-12:35 DEBATE 3 – T-ALL: where are we going now?
Chair: Nicolas Boissel (Paris)

Audience votes

11:55-12:10 Standard and new options for T-ALL
David Teachey (Philadelphia)
12:10-12:15 Discussion

12:15-12:30 Targeting T cell Malignancies with CRISPR/Cas9 Gene Edited Universal CART
John DiPersio (Saint-Louis)
12:30-12:35 Discussion

Audience votes again

12:35-12:45 Closing remarks

MEETING CLOSURE